Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EpiPolyPharma

Financiado

Development of dual-targeting epigenetic modulators for polypharmacology-based c...

Development of dual-targeting epigenetic modulators for polypharmacology-based cancer therapy Cancer is a multifactorial disorder involving different genetic and epigenetic alterations. Since epigenetic modifications are brought about by multiple enzymes working synergistically, multitargeting compounds may be particularly... ver más

30/09/2024

UNIROMA1

173K€

Presupuesto del proyecto: 173K€

Líder del proyecto

UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-09-30

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021 ExpectedOutcome:

I+D

Cerrada hace 3 años

0% 100% 100%

2 Participantes

UNIROMA1

172.75K€ | Lider

UNIPV

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2013-48397-R SINTESIS DE NUEVOS MODULADORES DE ENZIMAS EPIGENETICAS INSPI... 363K€ Cerrado

SAF2010-17935 DISEÑO Y SINTESIS DE NUEVOS MODULADORES DE ENZIMAS EPIGENETI... 363K€ Cerrado

SAF2017-85330-R DESARROLLO DE NUEVAS MOLECULAS, MODULADORES EPIGENETICOS, PA... 121K€ Cerrado

ChromTrace Tracing epigenetic evolution of triple negative breast cance... 2M€ Cerrado

PID2021-125282OB-I00 USO DE APROXIMACIONES DE CELULA UNICA PARA DECIFRAR LA EPIGE... 472K€ Cerrado

TARGETSET Commercial feasibility of targeting the histone methyltransf... 150K€ Cerrado

Duración del proyecto: 27 meses Fecha Inicio: 2022-06-16
Fecha Fin: 2024-09-30

Líder del proyecto

UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 173K€

Descripción del proyecto Cancer is a multifactorial disorder involving different genetic and epigenetic alterations. Since epigenetic modifications are brought about by multiple enzymes working synergistically, multitargeting compounds may be particularly effective to acutely interfere with aberrant processes. The simultaneous inhibition of two or more enzymes by a single molecule provides improved therapeutic efficacy compared to single-target inhibitors, along with reduced insurgence of drug resistance. Through this project, I aim at developing novel therapeutics targeting protein (de)methylation and (de)acetylation for application in cancer therapy. I will synthesise and evaluate hybrid molecules inhibiting two enzymes at the same time. I will develop two classes of compounds targeting the Lysine-specific histone demethylase 1A (LSD1) and either Protein arginine N-methyltransferase 5 (PRMT5) or Histone deacetylases 1-2 (HDAC1-2). These enzymes cooperate in different pathways that lead to cancer insurgence and progression, hence dual targeting represents a successful strategy to counteract tumour growth. To achieve the outlined aims, I will employ a multidisciplinary approach requiring the fusion of knowledge and tools from medicinal chemistry, biochemistry, biophysics, molecular and cell biology. Through the employment of cutting-edge synthetic approaches, I will prepare LSD1/PRMT5 and LSD1/HDAC1-2 inhibitors which will be assessed through multiple biochemical and biophysical assays. I will also employ native mass spectrometry to investigate their mode of action in the context of the multi-protein complexes formed by the protein targets. The most promising inhibitors will be evaluated in cellular assays to assess their anticancer properties and their effects on transcriptional regulation. This project will open innovative avenues for personalised therapies and provide additional weapons to overcome drug resistance, along with adding new knowledge on the epigenetic mechanisms of cancer.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores